Literature DB >> 18722302

Causes of early failure in a multicenter clinical trial of hip resurfacing.

Paul R Kim1, Paul E Beaulé, G Yves Laflamme, Michael Dunbar.   

Abstract

The purpose of this study was to evaluate the clinical outcomes and possible causes of early failure in a multicenter trial of metal-on-metal hip resurfacing. Two hundred patients were prospectively enrolled and followed for an average of 31.2 months (range, 12-54 months). Of 200 patients, 14 (7.0%) required revision surgery at a mean time of 19.5 months (range, 3-47 months). Patients with failures were significantly younger and heavier than the nonfailures, and all were male. Patients who were revised did not differ from those who were not revised in terms of radiographic outcomes, but they did report lower functional outcome scores at all preoperative and postoperative testing intervals. Most failures (10/14) were related to early acetabular loosening. The learning curve was likely a factor in these cup failures. This report highlights the importance of patient selection and surgical technique in hip resurfacing arthroplasty. It is anticipated that further surgical experience will lead to a reduction in this high early failure rate.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18722302     DOI: 10.1016/j.arth.2008.05.022

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  27 in total

1.  [Durom™ hip resurfacing. Short- to midterm clinical and radiological outcome].

Authors:  J Goronzy; M Stiehler; S Kirschner; K-P Günther
Journal:  Orthopade       Date:  2010-09       Impact factor: 1.087

Review 2.  Survival of hard-on-hard bearings in total hip arthroplasty: a systematic review.

Authors:  Michael G Zywiel; Siraj A Sayeed; Aaron J Johnson; Thomas P Schmalzried; Michael A Mont
Journal:  Clin Orthop Relat Res       Date:  2011-06       Impact factor: 4.176

3.  A simple technique for alignment in total hip resurfacing arthroplasty: technical note and preliminary report.

Authors:  Manuel Villanueva-Martínez; Antonio Ríos-Luna; Angel Villamor-Pérez
Journal:  HSS J       Date:  2009-06-09

Review 4.  Radiology of the resurfaced hip.

Authors:  Luthfur Rahman; Margaret Hall-Craggs; Sarah K Muirhead-Allwood
Journal:  Skeletal Radiol       Date:  2011-04-05       Impact factor: 2.199

Review 5.  Hip resurfacing: a systematic review of literature.

Authors:  Régis Pailhé; Akash Sharma; Nicolas Reina; Etienne Cavaignac; Philippe Chiron; Jean-Michel Laffosse
Journal:  Int Orthop       Date:  2012-10-26       Impact factor: 3.075

6.  Radiological validation of a fluoroscopic guided technique for femoral implant positioning during hip resurfacing.

Authors:  Philippe Chiron; Régis Pailhé; Nicolas Reina; David Ancelin; Akash Sharma; Laurent Maubisson; Jean-Michel Laffosse
Journal:  Int Orthop       Date:  2013-01-29       Impact factor: 3.075

7.  Reproducibility of radiographic assessment of femoral implant position after hip resurfacing arthroplasty: a pilot study.

Authors:  Régis Pailhé; Nicolas Reina; David Ancelin; Etienne Cavaignac; Laurent Maubisson; Akash Sharma; Philippe Chiron
Journal:  Eur J Orthop Surg Traumatol       Date:  2013-04-05

8.  Survivorship and clinical outcome of Birmingham hip resurfacing: a minimum ten years' follow-up.

Authors:  Md Quamar Azam; Stephen McMahon; Gabrielle Hawdon; Sukesh Rao Sankineani
Journal:  Int Orthop       Date:  2015-03-31       Impact factor: 3.075

9.  The First SICOT Oral Presentation Award 2011: imageless computer-assisted femoral component positioning in hip resurfacing: a prospective randomised trial.

Authors:  Maik Stiehler; Jens Goronzy; Albrecht Hartmann; Frank Krummenauer; Klaus-Peter Günther
Journal:  Int Orthop       Date:  2013-02-06       Impact factor: 3.075

10.  Outcome of primary resurfacing hip replacement: evaluation of risk factors for early revision.

Authors:  Gareth H Prosser; Piers J Yates; David J Wood; Stephen E Graves; Richard N de Steiger; Lisa N Miller
Journal:  Acta Orthop       Date:  2010-02       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.